These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 23846410

  • 1. S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis.
    Achouiti A, Föll D, Vogl T, van Till JW, Laterre PF, Dugernier T, Wittebole X, Boermeester MA, Roth J, van der Poll T, van Zoelen MA.
    Shock; 2013 Sep; 40(3):188-94. PubMed ID: 23846410
    [Abstract] [Full Text] [Related]

  • 2. Systemic and local high mobility group box 1 concentrations during severe infection.
    van Zoelen MA, Laterre PF, van Veen SQ, van Till JW, Wittebole X, Bresser P, Tanck MW, Dugernier T, Ishizaka A, Boermeester MA, van der Poll T.
    Crit Care Med; 2007 Dec; 35(12):2799-804. PubMed ID: 17901841
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
    Kim HS, Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY.
    Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.
    Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A, Mrozek S, Perbet S, Cayot-Constantin S, Chartier C, Sapin V, Bazin JE, Constantin JM.
    Crit Care Med; 2011 Mar; 39(3):480-8. PubMed ID: 21220996
    [Abstract] [Full Text] [Related]

  • 8. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B.
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [Abstract] [Full Text] [Related]

  • 9. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, Roth J, Foell D.
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.
    Kocsis AK, Szabolcs A, Hofner P, Takács T, Farkas G, Boda K, Mándi Y.
    Pancreatology; 2009 Dec; 9(4):383-91. PubMed ID: 19451748
    [Abstract] [Full Text] [Related]

  • 12. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A.
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [Abstract] [Full Text] [Related]

  • 13. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
    Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS.
    Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869
    [Abstract] [Full Text] [Related]

  • 14. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A.
    Arthritis Res Ther; 2005 Nov; 7(4):R817-24. PubMed ID: 15987483
    [Abstract] [Full Text] [Related]

  • 15. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation.
    Buhimschi IA, Zhao G, Pettker CM, Bahtiyar MO, Magloire LK, Thung S, Fairchild T, Buhimschi CS.
    Am J Obstet Gynecol; 2007 Feb; 196(2):181.e1-13. PubMed ID: 17306673
    [Abstract] [Full Text] [Related]

  • 16. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
    Qi Y, Gong F, Zhang Q, Xie C, Wang W, Fu S.
    Arthritis Res Ther; 2012 Nov 21; 14(6):R251. PubMed ID: 23171632
    [Abstract] [Full Text] [Related]

  • 17. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease.
    Zakiyanov O, Kalousová M, Kříha V, Zima T, Tesař V.
    Kidney Blood Press Res; 2011 Nov 21; 34(6):457-64. PubMed ID: 21822023
    [Abstract] [Full Text] [Related]

  • 18. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome.
    Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, Roth J, Foell D.
    Crit Care Med; 2007 May 21; 35(5):1369-75. PubMed ID: 17414728
    [Abstract] [Full Text] [Related]

  • 19. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease.
    Uchiyama-Tanaka Y, Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, Matsubara H.
    Ther Apher Dial; 2008 Feb 21; 12(1):28-32. PubMed ID: 18257809
    [Abstract] [Full Text] [Related]

  • 20. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD.
    Boschetto P, Campo I, Stendardo M, Casimirri E, Tinelli C, Gorrini M, Ceconi C, Fucili A, Potena A, Papi A, Ballerin L, Fabbri LM, Luisetti M.
    Eur J Clin Invest; 2013 Jun 21; 43(6):562-9. PubMed ID: 23590548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.